(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLDCRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

https://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

https://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






Latest News Releases From The Newsroom

Helen of Troy Beats Estimates; Analysts Take Note of CAVA Group

July 10th, 2023

Helen of Troy Limited (Nasdaq: HELE) reported first-quarter fiscal 2024 adjusted earnings per share (EPS) of $1.94, surpassing the consensus estimate of $1.60. Looking ahead, for the full-year fiscal 2024, the company expects adjusted EPS to fall . Read more

Q2: NanoString and ASE Technology Unveil Financial Figures

July 10th, 2023

NanoString Technologies, Inc. (Nasdaq: NSTG) has reported strong preliminary financial figures for the second quarter of 2023. The company expects Q2 revenue to surpass $44 million, reflecting a remarkable year-on-year growth of approximately 37%. Th. Read more

Nanobiotix Skyrockets On Multi-Million Dollar NBTXR3 Deal

July 10th, 2023

Shares of Nanobiotix S.A. (Nasdaq: NBTX) surged over 50% in pre-market trading following the announcement of a global licensing and commercialization agreement with Janssen Pharmaceutica NV, a subsidiary of Johnson & Johnson (NYSE: JNJ). The agree. Read more

Earnings Preview: MillerKnoll, AngioDynamics, and Theratechnologies

July 09th, 2023

On Wednesday, July 12, several companies are expected to report their financial results, including: MillerKnoll, Inc. (Nasdaq: MLKN), a consumer goods company, is set to release its financial results for the fourth quarter and full-year fiscal 202. Read more

Helen of Troy, WD-40, E2open, CalAmp, and VOXX Set to Release Earnings: A Preview

July 09th, 2023

Several companies are expected to report their financial results on Monday, July 10, including: Helen of Troy Limited (Nasdaq: HELE), a company operating in the consumer products industry, is set to release its first-quarter fiscal 2024 results be. Read more

SEC Charges Former Army Financial Counselor Who Defrauded Gold Star Family Members

July 07th, 2023

FOR IMMEDIATE RELEASE 2023-127 Washington D.C. / CRWE PRESS RELEASE / July 7, 2023 - The Securities and Exchange Commission today charged former U.S. Army financial counselor Caz L. Craffy for defrauding Gold Star family members and others b. Read more

Earnings Reaction: AZZ Disappoints; $5.25M Order Fuels Alpine 4

July 07th, 2023

AZZ Inc. (NYSE: AZZ) reported first-quarter fiscal 2024 earnings per share (EPS) of $1.14 and sales of $390.87 million, slightly below the consensus EPS of $1.16 on revenue of $396.65 million. Despite the earnings results, the company is. Read more

Market Movers: ZyVersa and Castle Biosciences Share the Spotlight

July 07th, 2023

Shares of ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) surged over 20% in early trade after the European Patent Office granted a patent (number EP 2 836 221) for its Cholesterol Efflux Mediator VAR 200 in the treatment of diabetic nephropathy/diabetic k. Read more

Morgan Stanley's Bullish Stance: Ford, General Motors, and Ferrari

July 07th, 2023

Ford Motor Company (NYSE: F), a renowned automobile manufacturer, was maintained with an Overweight rating by Morgan Stanley, who raised the price target from $14 to $16. Based on Thursday's closing price of $14.98, the adjusted price target indic. Read more

LEQEMBI Breakthrough: FDA Approves Eisai and Biogen's Alzheimer's Therapy

July 07th, 2023

Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) have received FDA approval for LEQEMBI (lecanemab-irmb), a groundbreaking treatment for Alzheimer's disease (AD), the most common type of dementia. LEQEMBI is the first approved therapy to demonstrate a . Read more